专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06465687B1 Thyroid receptor ligands and method 失效
标题翻译：甲状腺受体配体及方法
公开(公告)号：US06465687B1
公开(公告)日：2002-10-15
申请号：US09445888
申请日：2000-03-20
申请人： Yi-Lin Li , Ye Liu , Asa Hedfors , Johan Malm , Charlotta Mellin , Minsheng Zhang
发明人： Yi-Lin Li , Ye Liu , Asa Hedfors , Johan Malm , Charlotta Mellin , Minsheng Zhang
IPC分类号： C07C5900
CPC分类号： C07F9/3882 , C07C43/295 , C07C59/68 , C07C65/24 , C07C255/37 , C07F9/4056
摘要： Novel thyroid receptor ligands are provided which have the general formula (I) where R1 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 3 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; n is an integer from 0 to 4; R4 is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, cyano, or a phosphonic acid or an ester thereof, or a pharmaceutically acceptible salt thereof. A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene, such as obesity, hypercholesterolemia, osteoporosis, hypothyroidism, and goiter, is also provided.
摘要翻译：提供了具有通式（I）的新型甲状腺受体配体，其中R 1是1至4个碳的烷基或3至7个碳的环烷基; R2和R3相同或不同，为氢，卤素，1〜3个碳的烷基或3〜5个碳的环烷基，R2和R3中的至少一个不是氢; n为0〜4的整数; R4是脂族烃，芳烃，其羧酸酯，烯基羧酸或其酯，羟基，卤素，氰基或膦酸或其酯，或其药学上可接受的盐。还提供了用于治疗与代谢功能障碍相关的疾病或依赖于T3调节基因如肥胖，高胆固醇血症，骨质疏松症，甲状腺机能减退和甲状腺肿的表达的方法。

2. 发明授权

US07288571B2 Thyroid receptor ligands and method II 失效
标题翻译：甲状腺受体配体及方法二
公开(公告)号：US07288571B2
公开(公告)日：2007-10-30
申请号：US11189654
申请日：2005-07-26
申请人： Jon Hangeland , Minsheng Zhang , Yolanda Caringal , Denis Ryono , Yi-Lin Li , Johan Malm , Ye Liu , Neeraj Garg , Chris Litten , Ana Maria Garcia Collazo , Konrad Koehler
发明人： Jon Hangeland , Minsheng Zhang , Yolanda Caringal , Denis Ryono , Yi-Lin Li , Johan Malm , Ye Liu , Neeraj Garg , Chris Litten , Ana Maria Garcia Collazo , Konrad Koehler
IPC分类号： A61K31/18 , C07C311/50
CPC分类号： C07D207/27 , C07C235/32 , C07C235/52 , C07C307/06 , C07C311/51 , C07C323/41 , C07C323/60 , C07D207/09 , C07D211/24 , C07D211/34 , C07D211/58 , C07D211/96 , C07D213/40 , C07D223/12 , C07D231/38 , C07D233/64 , C07D257/04 , C07D285/06 , C07D285/135 , C07D295/13 , C07D295/185 , C07D333/20
摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereolsom thereof; or when n is equal to or greater than one, R4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5—H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
摘要翻译：提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， SUB 2和R 3不是氢; R 4是羧酸酰胺（CONR'R“）或酰基磺酰胺（CONHSO 2 R'）衍生物或其药学上可接受的盐及其所有立体异构体; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构的其它基团（其中R 5 -H）。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以治疗有效量。与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及青光眼，充血性心力衰竭和皮肤疾病。

3. 发明申请

US20050282872A1 Novel thyroid receptor ligands and method II 失效
标题翻译：新型甲状腺受体配体及方法二
公开(公告)号：US20050282872A1
公开(公告)日：2005-12-22
申请号：US11189654
申请日：2005-07-26
申请人： Jon Hangeland , Minsheng Zhang , Yolanda Caringal , Denis Ryono , Yi-Lin Li , Johan Malm , Ye Liu , Neeraj Garg , Chris Litten , Ana Collazo , Konrad Koehler
发明人： Jon Hangeland , Minsheng Zhang , Yolanda Caringal , Denis Ryono , Yi-Lin Li , Johan Malm , Ye Liu , Neeraj Garg , Chris Litten , Ana Collazo , Konrad Koehler
IPC分类号： C07D233/88 , A61K31/381 , A61K31/40 , A61K31/41 , A61K31/415 , A61K31/4168 , A61K31/433 , A61K31/44 , A61K31/4409 , A61K31/495 , A61K31/55 , A61K45/00 , A61P3/04 , A61P3/06 , A61P5/14 , A61P9/06 , A61P9/10 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P19/10 , A61P25/24 , A61P27/06 , A61P35/00 , C07C235/32 , C07C235/34 , C07C235/52 , C07C307/06 , C07C311/00 , C07C311/51 , C07C323/41 , C07C323/59 , C07C323/60 , C07D207/09 , C07D207/26 , C07D207/27 , C07D211/24 , C07D211/34 , C07D211/58 , C07D211/60 , C07D211/96 , C07D213/38 , C07D213/40 , C07D213/74 , C07D223/12 , C07D231/38 , C07D233/54 , C07D241/04 , C07D257/04 , C07D285/06 , C07D285/12 , C07D285/125 , C07D285/135 , C07D295/13 , C07D295/185 , C07D333/20 , C07D333/34 , A61K31/426
CPC分类号： C07D207/27 , C07C235/32 , C07C235/52 , C07C307/06 , C07C311/51 , C07C323/41 , C07C323/60 , C07D207/09 , C07D211/24 , C07D211/34 , C07D211/58 , C07D211/96 , C07D213/40 , C07D223/12 , C07D231/38 , C07D233/64 , C07D257/04 , C07D285/06 , C07D285/135 , C07D295/13 , C07D295/185 , C07D333/20
摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or differential hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid thereof; or when n is equal to or greater than one, R4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5—H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
摘要翻译：提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3是相同或不同的氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， 2和R 3不是氢; R 4是其羧酸; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构的其它基团（其中R 5 -H）。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以治疗有效量。与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及青光眼，充血性心力衰竭和皮肤疾病。

4. 发明授权

US06989402B1 Thyroid receptor ligands and method II 失效
标题翻译：甲状腺受体配体及方法二
公开(公告)号：US06989402B1
公开(公告)日：2006-01-24
申请号：US09868889
申请日：1999-12-23
申请人： Jon Hangeland , Minsheng Zhang , Yolanda Caringal , Denis Ryono , Yi-Lin Li , Johan Malm , Ye Liu , Neeraj Garg , Chris Litten , Ana Maria Garcia Collazo , Konrad Koehler
发明人： Jon Hangeland , Minsheng Zhang , Yolanda Caringal , Denis Ryono , Yi-Lin Li , Johan Malm , Ye Liu , Neeraj Garg , Chris Litten , Ana Maria Garcia Collazo , Konrad Koehler
IPC分类号： A61K31/44 , A61K31/192 , A61K31/40 , A61K31/4174 , C07D211/56 , C07D213/72 , C07D229/38 , C07D265/30 , C07D241/04 , C07D207/14
CPC分类号： C07D207/27 , C07C235/32 , C07C235/52 , C07C307/06 , C07C311/51 , C07C323/41 , C07C323/60 , C07D207/09 , C07D211/24 , C07D211/34 , C07D211/58 , C07D211/96 , C07D213/40 , C07D223/12 , C07D231/38 , C07D233/64 , C07D257/04 , C07D285/06 , C07D285/135 , C07D295/13 , C07D295/185 , C07D333/20
摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
摘要翻译：提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， SUB 2和R 3不是氢; R 4是羧酸酰胺（CONR'R“）或酰基磺酰胺（CONHSO 2 R'）衍生物或其药学上可接受的盐及其所有立体异构体; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（例如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构（其中R 5 = H）的其它基团。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以治疗有效量。与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及青光眼，充血性心力衰竭和皮肤疾病。

5. 发明授权

US08711906B2 Tracking data eye operating margin for steady state adaptation 有权
标题翻译：跟踪数据眼动操作裕度进行稳态调整
公开(公告)号：US08711906B2
公开(公告)日：2014-04-29
申请号：US12941217
申请日：2010-11-08
申请人： Mohammad Mobin , Ye Liu , Amaresh Malipatil
发明人： Mohammad Mobin , Ye Liu , Amaresh Malipatil
IPC分类号： H04B1/38 , H04L5/16
CPC分类号： H04L25/03012 , H04L2025/03439
摘要： In described embodiments, a transceiver includes an eye monitor and margin detector having one or more samplers with corresponding logic. One or more programmable provisioning parameters are defined based on a pre-defined minimum target operating margin for acceptable noise and jitter margins. For example, two programmable provisioning parameters, phase and voltage, correspond with thresholds for margin samplers placed within the eye. Initially, the transceiver applies equalization, after which an inner eye of the transceiver, as detected by the eye monitor, is relatively open with some margin for supporting channels. If the receiver margin goes below this target margin, the eye closes, which is registered by the samplers. In the presence of spectrally rich input data, if the receiver margin goes below this target margin, an updated adaptation of equalizer or other circuit parameters might be initiated; else, adaptation is not generally required.
摘要翻译：在所描述的实施例中，收发器包括具有具有相应逻辑的一个或多个采样器的眼睛监视器和边缘检测器。基于用于可接受的噪声和抖动余量的预定义的最小目标操作裕度来定义一个或多个可编程供应参数。例如，两个可编程供应参数（相位和电压）对应于放置在眼睛内的余量采样器的阈值。最初，收发机应用均衡，之后由眼睛监视器检测到的收发器的内眼相对开放，具有用于支持信道的一些余量。如果接收机边缘低于该目标边距，则眼睛关闭，由采样器注册。在存在频谱丰富的输入数据的情况下，如果接收器余量低于该目标余量，则可以启动更新的均衡器或其他电路参数的适配; 否则，通常不需要适应。

6. 发明授权

US08703194B2 Stimulus-responsive biodegradable polymers and methods of preparation 有权
标题翻译：刺激反应性生物降解聚合物及其制备方法
公开(公告)号：US08703194B2
公开(公告)日：2014-04-22
申请号：US11934638
申请日：2007-11-02
申请人： Ye Liu , Decheng Wu , Chaobin He
发明人： Ye Liu , Decheng Wu , Chaobin He
IPC分类号： A61K9/14
CPC分类号： A61K9/1075 , A61K9/06 , A61K47/34 , C08F120/10 , C08F120/54
摘要： There is presently provided a stimulus-responsive polymer comprising a biodegradable polymer backbone and a stimulus-responsive pendant group attached to the biodegradable polymer backbone, wherein the biodegradable polymer backbone comprises a poly(amino ester) or a poly(amido amine), the poly(amido amine) optionally comprising a disulfide linkage in the backbone.
摘要翻译：目前提供了包含可生物降解的聚合物主链和连接到可生物降解的聚合物主链的刺激响应侧基的刺激响应性聚合物，其中生物可降解的聚合物主链包含聚（氨基酯）或聚（酰氨基胺），聚（酰胺胺），其任选地在主链中包含二硫键。

7. 发明授权

US08586827B2 Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same 有权
公开(公告)号：US08586827B2
公开(公告)日：2013-11-19
申请号：US12894655
申请日：2010-09-30
申请人： Lan Tang , Ye Liu , Junxin Duan , Wenping Wu , Randall Kramer
发明人： Lan Tang , Ye Liu , Junxin Duan , Wenping Wu , Randall Kramer
IPC分类号： C12P21/02 , C12N15/56 , C12N15/82 , C12N9/42 , A01N63/00
CPC分类号： C12P19/14 , C07K14/37 , C12N9/2437 , C12N15/8246 , C12P7/14 , C12P19/02
摘要： The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

8. 发明授权

US08586346B2 Polypeptides having cellobiohydrolase activity and polynucleotides encoding same 有权
公开(公告)号：US08586346B2
公开(公告)日：2013-11-19
申请号：US13596879
申请日：2012-08-28
申请人： Ye Liu , Paul Harris , Lan Tang , Wenping Wu
发明人： Ye Liu , Paul Harris , Lan Tang , Wenping Wu
IPC分类号： A01H5/00 , C12N15/11 , C12N15/55 , C12N15/63 , C12N9/00 , C12N1/00
CPC分类号： C12N9/2437 , C12N1/22 , C12N15/1137 , C12N2310/14 , C12P7/10 , C12P19/02 , C12P19/14 , C12Y302/01091 , C12Y302/01099 , Y02E50/16
摘要： The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

9. 发明申请

US20130296444A1 COPOLYMER, COMPOSITION AND METHOD FOR MODIFYING RHEOLOGY 有权
标题翻译：共聚物，组合物和修饰流变学方法
公开(公告)号：US20130296444A1
公开(公告)日：2013-11-07
申请号：US13997179
申请日：2011-12-21
申请人： Decheng Wu , Ye Liu , Jianwei Xu , Chaobin He
发明人： Decheng Wu , Ye Liu , Jianwei Xu , Chaobin He
IPC分类号： A61K8/81 , A61K47/32
CPC分类号： A61K8/8152 , A61K47/32 , A61K2800/10 , A61K2800/48 , A61Q19/00 , C08F290/148
摘要： A copolymer for modifying rheology is formed of monomer units consisting essentially of at least one first monomer unit comprising a polyhedral oligomeric silsesquioxane having an ethylenically unsaturated radical; at least one second monomer unit comprising an unsaturated oligo-poly(dimethyl siloxane)(meth)acrylate; and a sufficient amount of at least one unsaturated water-soluble monomer, such that the copolymer is soluble in water. A composition may comprise an electrolyte and the copolymer. The rheology of an environment comprising an electrolyte may be modified by adding the copolymer to the environment.
摘要翻译：用于改性流变学的共聚物由基本上由至少一种第一单体单元组成的单体形成，所述第一单体单元包含具有烯属不饱和基团的多面体低聚倍半硅氧烷; 包含不饱和低聚 - 聚（二甲基硅氧烷）（甲基）丙烯酸酯的至少一个第二单体单元; 和足够量的至少一种不饱和水溶性单体，使得共聚物可溶于水。组合物可以包含电解质和共聚物。包含电解质的环境的流变学可以通过将共聚物加入到环境中进行改性。

10. 发明授权

US08496796B2 Composite films comprising carbon nanotubes and polymer 有权
标题翻译：包含碳纳米管和聚合物的复合膜
公开(公告)号：US08496796B2
公开(公告)日：2013-07-30
申请号：US12738602
申请日：2007-10-17
申请人： Xu Li , Chaobin He , Decheng Wu , Ye Liu
发明人： Xu Li , Chaobin He , Decheng Wu , Ye Liu
IPC分类号： C25D13/02
CPC分类号： C25D13/02 , B82Y30/00 , C08J5/005 , C08K3/041 , C08K9/04 , C09D5/4461 , C09D5/448 , C09D7/62 , C09D7/70 , C09D179/08 , C25D13/04 , C25D13/22 , Y10T428/249948
摘要： A process for forming a composite film on a substrate comprises providing a suspension comprising an ionised polymer and functionalised carbon nanotubes in a solvent, at least partially immersing the substrate and a counterelectrode in the suspension, and applying a voltage between the substrate and the counterelectrode so as to form the composite film on the substrate. Electrical charges on the polymer and on the nanotubes have the same sign and the voltage is applied such that the charge on the substrate has the opposite sign to the charge on the polymer and the nanotubes.
摘要翻译：在基材上形成复合膜的方法包括在溶剂中提供包含电离聚合物和官能化碳纳米管的悬浮液，至少部分地将基材和反电极浸渍在悬浮液中，并在基板和反电极之间施加电压，因此以在基板上形成复合膜。聚合物和纳米管上的电荷具有相同的符号，施加电压使得基底上的电荷与聚合物和纳米管上的电荷具有相反的符号。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式